Halozyme Therapeutics (HALO) Debt/Equity Ratio: History & Chart

Halozyme Therapeutics, Inc.(HALO)

Biotechnology · San Diego, CA

$109.48+1.17 (+1.08%)

Delayed quote: Oct 6, 2026, 1:10 PM EDT

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

San Diego, CA

423 employees

www.halozyme.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen I. Torley

View full financials

HALO Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

14.95

DEBT TO EQUITY RATIO AVG TTM

15.23

DEBT TO EQUITY RATIO AVG 3Y

7.52

DEBT TO EQUITY RATIO AVG 5Y

7.22

DEBT TO EQUITY RATIO AVG 10Y

4.65

DEBT TO EQUITY RATIO AVG 15Y

2.65

DEBT TO EQUITY RATIO AVG 20Y

1.90

CURRENT VS TTM AVG

-1.80%

CURRENT VS 3Y AVG

+98.79%

CURRENT VS 5Y AVG

+107.18%

CURRENT VS 10Y AVG

+221.59%

CURRENT VS 15Y AVG

+464.03%

CURRENT VS 20Y AVG

+685.21%

SECTOR MEDIAN · HEALTHCARE

0.11

median of 714 covered companies

CURRENT VS SECTOR MEDIAN

+13495.25%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Halozyme Therapeutics, Inc. (HALO)	$12.99B	14.95	15.23	7.52	7.22
Tempus AI, Inc. (TEM)vs ›	$13.06B	3.25	5.51	5.51	5.51
BridgeBio Pharma, Inc. (BBIO)vs ›	$13.07B	N/A	4.39	4.39	4.39
Corcept Therapeutics Incorporated (CORT)vs ›	$12.86B	0.01	0.01	0.01	0.00
Penumbra, Inc. (PEN)vs ›	$12.52B	0.14	0.17	0.20	0.18
ICON Public Limited Company (ICLR)vs ›	$12.51B	0.37	0.39	0.44	0.45
Baxter International Inc. (BAX)vs ›	$12.50B	1.56	1.78	2.05	1.83
Summit Therapeutics Inc. (SMMT)vs ›	$13.51B	0.03	0.03	1.38	0.93
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.42B	1.17	1.60	3.59	3.91
Encompass Health Corporation (EHC)vs ›	$12.33B	1.09	1.21	1.62	1.75

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Halozyme Therapeutics, Inc. (HALO)

$12.99B

14.95

15.23

7.52

7.22

Tempus AI, Inc. (TEM)vs ›

$13.06B

3.25

5.51

BridgeBio Pharma, Inc. (BBIO)vs ›

$13.07B

N/A

4.39

Corcept Therapeutics Incorporated (CORT)vs ›

$12.86B

0.01

0.00

Penumbra, Inc. (PEN)vs ›

$12.52B

0.14

0.17

0.20

0.18

ICON Public Limited Company (ICLR)vs ›

$12.51B

0.37

0.39

0.44

0.45

Baxter International Inc. (BAX)vs ›

$12.50B

1.56

1.78

2.05

1.83

Summit Therapeutics Inc. (SMMT)vs ›

$13.51B

0.03

1.38

0.93

BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›

$12.42B

1.17

1.60

3.59

3.91

Encompass Health Corporation (EHC)vs ›

$12.33B

1.09

1.21

1.62

1.75

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The debt to equity ratio for HALO stock is 14.95.

Is Halozyme Therapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 14.95 is 107% above its 5-year average of 7.22, near the low end of its 5-year range (3.00–43.89).

What is the TTM average debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The TTM average debt to equity ratio for HALO stock is 15.23.

What is the 3Y average debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The 3Y average debt to equity ratio for HALO stock is 7.52.

What is the 5Y average debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The 5Y average debt to equity ratio for HALO stock is 7.22.

What is the 10Y average debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The 10Y average debt to equity ratio for HALO stock is 4.65.

What is the 15Y average debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The 15Y average debt to equity ratio for HALO stock is 2.65.

What is the 20Y average debt to equity ratio for Halozyme Therapeutics, Inc. (HALO)?

The 20Y average debt to equity ratio for HALO stock is 1.90.

DATE	DEBT TO EQUITY RATIO
2026-06-30	14.95
2026-03-31	9.76
2025-12-31	43.89
2025-09-30	3.00
2025-06-30	4.54
2025-03-31	3.13
2024-12-31	4.14
2024-09-30	3.32
2024-06-30	5.19
2024-03-31	8.44
2023-12-31	17.89
2023-09-30	6.01
2023-06-30	9.91
2023-03-31	22.69
2022-12-31	8.87
2022-09-30	15.51
2022-06-30	4.25
2022-03-31	3.37
2021-12-31	4.45
2021-09-30	3.11
2021-06-30	7.30
2021-03-31	12.93
2020-12-31	2.63
2020-09-30	3.98
2020-06-30	3.69
2020-03-31	6.71
2019-12-31	4.39
2019-09-30	0.26
2019-06-30	0.33
2019-03-31	0.41
2018-12-31	0.51
2018-09-30	0.61
2018-06-30	0.65
2018-03-31	0.70
2017-12-31	0.97
2017-09-30	2.86
2017-06-30	3.63
2017-03-31	-3.66
2016-12-31	-6.67
2016-09-30	-17.69
2016-06-30	20.98
2016-03-31	6.65
2015-12-31	1.16
2015-09-30	1.57
2015-06-30	0.99
2015-03-31	1.32
2014-12-31	1.21
2014-09-30	1.25
2014-06-30	0.90
2014-03-31	0.75
2013-12-31	-2.49
2013-09-30	-9.27
2013-06-30	2.86
2013-03-31	0.98
2012-12-31	0.64
2012-09-30	0.00
2012-06-30	0.00
2012-03-31	0.00
2011-12-31	0.00
2011-09-30	0.00
2011-06-30	0.00
2011-03-31	0.00
2010-12-31	0.00
2010-09-30	0.00
2010-06-30	0.00
2010-03-31	0.00
2009-12-31	0.00
2009-09-30	0.00
2009-06-30	0.00
2009-03-31	0.00
2008-12-31	0.00
2008-09-30	0.00
2008-06-30	0.00
2008-03-31	0.00
2007-12-31	0.00
2007-09-30	0.00
2007-06-30	0.00
2007-03-31	0.00
2006-12-31	0.00
2006-09-30	0.00
2006-06-30	0.00
2006-03-31	0.00
2005-12-31	0.00
2005-09-30	0.00
2005-06-30	0.00
2005-03-31	0.00
2004-12-31	0.00
2004-09-30	0.00
2004-06-30	0.00
2004-03-31	19.53
2003-12-31	0.00
2003-09-30	0.00
2003-06-30	0.00
2003-03-31	0.00
2002-12-31	0.00
2002-09-30	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

14.95

2026-03-31

9.76

2025-12-31

43.89

2025-09-30

3.00

2025-06-30

4.54

2025-03-31

3.13

2024-12-31

4.14

2024-09-30

3.32

2024-06-30

5.19

2024-03-31

8.44

2023-12-31

17.89

2023-09-30

6.01

2023-06-30

9.91

2023-03-31

22.69

2022-12-31

8.87

2022-09-30

15.51

2022-06-30

4.25

2022-03-31

3.37

2021-12-31

4.45

2021-09-30

3.11

2021-06-30

7.30

2021-03-31

12.93

2020-12-31

2.63

2020-09-30

3.98

2020-06-30

3.69

2020-03-31

6.71

2019-12-31

4.39

2019-09-30

0.26

2019-06-30

0.33

2019-03-31

0.41

2018-12-31

0.51

2018-09-30

0.61

2018-06-30

0.65

2018-03-31

0.70

2017-12-31

0.97

2017-09-30

2.86

2017-06-30

3.63

2017-03-31

-3.66

2016-12-31

-6.67

2016-09-30

-17.69

2016-06-30

20.98

2016-03-31

6.65

2015-12-31

1.16

2015-09-30

1.57

2015-06-30

0.99

2015-03-31

1.32

2014-12-31

1.21

2014-09-30

1.25

2014-06-30

0.90

2014-03-31

0.75

2013-12-31

-2.49

2013-09-30

-9.27

2013-06-30

2.86

2013-03-31

0.98

2012-12-31

0.64

2012-09-30

0.00

2012-06-30

0.00

2012-03-31

0.00

2011-12-31

0.00

2011-09-30

0.00

2011-06-30

0.00

2011-03-31

0.00

2010-12-31

0.00

2010-09-30

0.00

2010-06-30

0.00

2010-03-31

0.00

2009-12-31

0.00

2009-09-30

0.00

2009-06-30

0.00

2009-03-31

0.00

2008-12-31

0.00

2008-09-30

0.00

2008-06-30

0.00

2008-03-31

0.00

2007-12-31

0.00

2007-09-30

0.00

2007-06-30

0.00

2007-03-31

0.00

2006-12-31

0.00

2006-09-30

0.00

2006-06-30

0.00

2006-03-31

0.00

2005-12-31

0.00

2005-09-30

0.00

2005-06-30

0.00

2005-03-31

0.00

2004-12-31

0.00

2004-09-30

0.00

2004-06-30

0.00

2004-03-31

19.53

2003-12-31

0.00

2003-09-30

0.00

2003-06-30

0.00

2003-03-31

0.00

2002-12-31

0.00

2002-09-30

0.00

Debt to Equity Ratio: 14.95

HALO Debt to Equity Ratio

HALO Average Debt to Equity Ratio Chart

HALO Current vs Average Debt to Equity Ratio Chart

HALO Debt to Equity Ratio Metrics

HALO Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

HALO Debt to Equity Ratio History

Related Metrics